Company Filing History:
Years Active: 2022-2025
Title: ChangHung Chen: Innovator in Cancer Therapy
Introduction
ChangHung Chen is a prominent inventor based in Blacksburg, Virginia. He has made significant contributions to the field of cancer therapy through his innovative research and development of chimeric antigen receptors (CARs). With a total of two patents to his name, Chen is recognized for his groundbreaking work in the medical field.
Latest Patents
ChangHung Chen's latest patents include "ROR-1 specific chimeric antigen receptors and uses thereof." This patent provides chimeric antigen receptors designed for cancer therapy, specifically CARs that contain a single-chain variable fragment (scFv) derived from an anti-ROR-1 monoclonal antibody. The patent also details immune effector cells that incorporate these CARs and methods for treating proliferative disorders. Another notable patent is "Fusion constructs and methods of using thereof." This patent describes a composition that includes a fusion protein or its variants, which combines an anti-PD1 antibody with a TGF-β trap. It also outlines methods for using this composition in cancer treatment.
Career Highlights
ChangHung Chen is currently employed at Precigen, Inc., where he continues to advance his research in cancer therapies. His work has positioned him as a key figure in the development of innovative treatments that aim to improve patient outcomes.
Collaborations
Throughout his career, Chen has collaborated with notable colleagues, including Rutul R Shah and Helen Sabzevari. These partnerships have further enhanced his research efforts and contributed to the success of his projects.
Conclusion
ChangHung Chen is a distinguished inventor whose work in cancer therapy has the potential to transform treatment options for patients. His innovative patents and collaborations reflect his commitment to advancing medical science.